Associate Director of Editorial, Print
Anita T. Shaffer is your lead editorial contact for OncologyLive®, a twice monthly clinical news publication. A 10-year veteran of MJH Life Sciences™, she has been at the helm of the publication since shortly after joining the company in 2010. Before becoming an oncology journalist, she held a variety of editorial positions at The Times of Trenton, including metro editor. Email: firstname.lastname@example.org
July 1st 2021
Novel therapeutic strategies are poised to expand in adjuvant settings for patients with early-stage disease facing recurrence risks in the treatment paradigms for a range of tumor types after positive data from large phase 3 clinical trials were highlighted at the 2021 American Society of Clinical Oncology Annual Meeting
April 26th 2021
The FDA’s Oncologic Drugs Advisory Committee is poised to move forward this week with a public review of 6 indications for immune checkpoint inhibitors granted under the agency’s accelerated approval process that later failed to reach thresholds for statistical significance for key end points in confirmatory clinical trials.
January 23rd 2021
Joseph V. Simone, MD, a pioneering clinical investigator and institutional leader in pediatric oncology who was recognized with a 2017 Giants of Cancer Care® award, died January 21 at the age of 85.
November 9th 2020
Maximilian Diehn, MD, PhD, discusses how the use of circulating tumor DNA to analyze minimal residual disease status in patients with lung cancer and other solid tumors is a rapidly developing field with the potential to further personalize treatment decisions about adjuvant therapy.
December 8th 2019
Mosunetuzumab, a novel bispecific antibody, generated durable responses in patients with highly refractory non-Hodgkin lymphomas, including complete remissions in 22.2% of those who had previously received chimeric antigen receptor T-cell therapy.
June 1st 2019
The development of tyrosine kinase inhibitors has revolutionized the treatment of EGFR-mutant non–small cell lung cancer in recent years, but new strategies are needed to overcome resistance mechanisms that promote disease recurrence.
May 7th 2014
Fresh insights into outcomes for patients with low-risk, HER2-positive breast cancer suggest that adjuvant chemotherapy regimens with or without trastuzumab (Herceptin) should be considered as options for managing this growing population
April 23rd 2014
Although the potential for next-generation sequencing of breast cancer tumors to improve treatment strategies is widely recognized, questions swirl about the optimal use of such increasingly available technologies in clinical practice for today's patients.
April 21st 2014
A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression
March 15th 2011
The search for a screening tool that can help detect lung cancers at early stages has been a focus of research aimed at the leading cause of cancer death in the United States.
March 7th 2011
There's been a flurry of activity in recent weeks when it comes to oncology drug filings at the FDA. While every application is unique, the agency is required to decide within 60 days whether a new drug application (NDA) will move forward for a full review.
March 6th 2011
Intellisphere, the publisher of Oncology Net Guide, will launch a dynamic Internet oncology news and information hub in March, along with a rechristened version of the print magazine linked to the vibrant new content on the Website.